We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDAK
126
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$1.96M 0.14%
+119,895
New +$2.14M
OBIO icon
127
Orchestra BioMed
OBIO
$238M
$1.95M 0.14%
197,173
-2,827
-1% -$27.9K
MDGL icon
128
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.89M 0.13%
23,700
+46
+0.2% +$3.97K
GYRE icon
129
Gyre Therapeutics
GYRE
$641M
$1.87M 0.13%
60,579
-16,914
-22% -$557K
QNCX icon
130
Quince Therapeutics
QNCX
$22.9M
$1.85M 0.13%
101
-2
-2% -$31.8K
MXCT icon
131
MaxCyte
MXCT
$112M
$1.83M 0.13%
+150,000
New +$2.26M
IRON icon
132
Disc Medicine
IRON
$2.96B
$1.7M 0.12%
14,035
-180
-1% -$24.6K
KALV
133
DELISTED
KalVista Pharmaceuticals
KALV
$1.69M 0.12%
96,576
-389
-0.4% -$7.88K
VTGN icon
134
VistaGen Therapeutics
VTGN
$9.89M
$1.65M 0.12%
20,023
-10,529
-34% -$915K
IFRX icon
135
InflaRx
IFRX
$250M
$1.63M 0.12%
631,048
-35,548
-5% -$93.6K
NTBL
136
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.62M 0.11%
22,595
-285
-1% -$22.2K
CERE
137
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$1.57M 0.11%
+53,370
New +$1.5M
AVTX icon
138
Avalo Therapeutics
AVTX
$965M
$1.57M 0.11%
250
-62
-20% -$503K
CYCN icon
139
Cyclerion Therapeutics
CYCN
$14.9M
$1.54M 0.11%
25,131
-365
-1% -$23.9K
PLRX icon
140
Pliant Therapeutics
PLRX
$64.4M
$1.46M 0.1%
86,712
-21,988
-20% -$467K
CASI
141
DELISTED
CASI Pharmaceuticals
CASI
$1.46M 0.1%
122,307
-4,508
-4% -$61K
BLCM
142
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.45M 0.1%
496,756
-3,244
-0.6% -$9.89K
GRI
143
GRI Bio
GRI
$2.44M
– –
0
– –
LONA
144
CALL
LeonaBio Inc
LONA
$66.3M
$1.41M 0.1%
+15,000
New +$1.53M
MBIO icon
145
Mustang Bio
MBIO
$4.32M
$1.36M 0.1%
675
-26
-4% -$55.9K
ASND icon
146
CALL
Ascendis Pharma A/S
ASND
$16B
$1.34M 0.09%
8,400
-200
-2% -$27.4K
OKUR
147
OnKure Therapeutics
OKUR
$154M
$1.3M 0.09%
+17,500
New +$1.49M
BDTX icon
148
Black Diamond Therapeutics
BDTX
$96.8M
$1.27M 0.09%
150,484
-3,457
-2% -$34.1K
DMAC icon
149
DiaMedica Therapeutics
DMAC
$342M
$1.25M 0.09%
311,041
-103,959
-25% -$398K
SLDB icon
150
Solid Biosciences
SLDB
$794M
$1.25M 0.09%
34,744
-10,301
-23% -$437K
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.